Oncotarget, Vol. 6, No. 11

www.impactjournals.com/oncotarget/

Identification of a novel synthetic lethality of combined
inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma
Ulrike Graab1, Heidi Hahn2, Simone Fulda1,3,4
1

Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Frankfurt, Germany

2

Institute of Human Genetics, University Medical Center, Goettingen, Germany

3

German Cancer Consortium (DKTK), Heidelberg, Germany

4

German Cancer Research Center (DKFZ), Heidelberg, Germany

Correspondence to:
Simone Fulda, e-mail: simone.fulda@kgu.de
Keywords: apoptosis, hedgehog, PI3K, rhabdomyosarcoma
Received: October 15, 2014	

Accepted: November 12, 2014	

Published: March 06, 2015

ABSTRACT
We previously reported that aberrant HH pathway activation confers a poor
prognosis in rhabdomyosarcoma (RMS). Searching for new treatment strategies
we therefore targeted HH signaling. Here, we identify a novel synthetic lethality
of concomitant inhibition of HH and PI3K/AKT/mTOR pathways in RMS by GLI1/2
inhibitor GANT61 and PI3K/mTOR inhibitor PI103. Synergistic drug interaction is
confirmed by calculation of combination index (CI < 0.2). Similarly, genetic silencing
of GLI1/2 significantly increases PI103-induced apoptosis. GANT61 and PI103 also
synergize to induce apoptosis in cultured primary RMS cells emphasizing the clinical
relevance of this combination. Importantly, GANT61/PI103 cotreatment suppresses
clonogenic survival, three-dimensional sphere formation and tumor growth in an
in vivo model of RMS. Mechanistic studies reveal that GANT61 and PI103 cooperate to
trigger caspase-dependent apoptosis via the mitochondrial pathway, as demonstrated
by several lines of evidence. First, GANT61/PI103 cotreatment increases mRNA
and protein expression of NOXA and BMF, which is required for apoptosis, since
knockdown of NOXA or BMF significantly reduces GANT61/PI103-induced apoptosis.
Second, GANT61/PI103 cotreatment triggers BAK/BAX activation, which contributes
to GANT61/PI103-mediated apoptosis, since knockdown of BAK provides protection.
Third, ectopic expression of BCL-2 or non-degradable phospho-mutant MCL-1
significantly rescue GANT61/PI103-triggered apoptosis. Fourth, GANT61/PI103
cotreatment initiate activation of the caspase cascade via apoptosome-mediated
cleavage of the initiator caspase-9, as indicated by changes in the cleavage pattern
of caspases (e.g. accumulation of the caspase-9 p35 cleavage fragment) upon addition
of the caspase inhibitor zVAD.fmk. Thus, combined GLI1/2 and PI3K/mTOR inhibition
represents a promising novel approach for synergistic apoptosis induction and tumor
growth reduction with implications for new treatment strategies in RMS.

PTCH mutations also give rise to the naevoid basal
cell carcinoma syndrome (NBCCS), known as Gorlin
syndrome, which is characterized by predispositions to
develop basal cell carcinomas (BCC), medulloblastoma
(MB) and RMS [4–6]. Mice heterozygous for PTCH
develop many of the features characteristic for NBCCS,
including RMS [5, 7]. PTCH is an essential component
of the HH signaling pathway, which is activated in
RMS i.e. via loss of chromosomal region 9p22 or by

INTRODUCTION
RMS, the most common pediatric soft-tissue
sarcoma, can be classified into two major subtypes,
i.e. alveolar (ARMS) and embryonal (ERMS), according
to the mutation status and histological features [1, 2].
One common mutation in RMS consists in the loss of
heterozygosity (LOH) at chromosomal region 9p22,
including the patched homolog (PTCH) locus [3].
www.impactjournals.com/oncotarget

8722

Oncotarget

amplification of the 12q13–15 region including the
GLI1 gene [3].
Canonical HH signaling pathway is activated via
binding of one of the ligands, e.g. sonic hedgehog (SHH),
to the transmembrane receptor PTCH. This leads to the
inactivation of PTCH and subsequently to the release of the
second transmembrane receptor smoothened (SMO)  [8].
SMO in turn modulates expression and/or post-translational
processing of the three GLI transcription factors. GLI1 and
GLI2 act mainly as transcriptional activators, while GLI3
functions as a transcriptional repressor [9]. The balance
between GLI activator and repressor forms results in
expression of HH target genes, including GLI1 and PTCH
[10]. Besides the canonical HH pathway, GLI proteins can
also be activated in a non-canonical and SMO-independent
manner via phosphorylation by PI3K/AKT [11, 12], mTOR/
S6 [13], RAS [11, 14] or MAPK/ERK [15].
Crosstalk between HH and PI3K/AKT/mTOR
signaling has been observed in different tumor entities. In
esophageal cancer, mTOR/S6 kinase signaling was shown
to phosphorylate GLI1, promoting its transcriptional
activity and tumor growth [13, 16]. In breast cancer, PI3K/
AKT signaling was reported to protect key elements of the
HH signaling pathway including GLI1 from proteasomal
degradation [17].
Programmed cell death is a fundamental cellular
program that is critical for maintaining tissue homeostasis
[18]. Two major apoptosis signaling pathways have
been characterized, i.e. the extrinsic, receptor-mediated
and the intrinsic, mitochondria-mediated pathway [19].
Mitochondrial apoptosis is controlled by various factors
including BCL-2 family proteins, which comprise anti­
apoptotic proteins such as BCL-2, BCL-XL and MCL-1
as well as proapoptotic proteins like BAK, BAX and
BH3-only proteins (i.e. BID, BIM, BMF and NOXA) [20].
Activation of BAX and BAK, for example upon binding of
BH3-only proteins, leads to mitochondrial outer membrane
permeabilization and release of mitochondrial intermembrane
space proteins such as cytochrome C that engages caspase-9
activation within the apoptosome complex [21].
Since we previously identified aberrant activation of
the HH pathway as a new poor prognostic factor in RMS [22],
we aimed at therapeutic targeting of this signaling cascade
in the present study. In view of mounting evidence showing
that canonical as well as non-canonical mechanisms can
cause HH activation, we inhibited HH signaling at different
levels alone and in combination with inhibition of HHinteracting pathways such as PI3K/AKT/mTOR signaling.

different HH components in a panel of ARMS and ERMS
cell lines. HH pathway activation was documented by
broad expression of GLI1 and GLI2, whereas GLI3 and
PTCH were differentially regulated and SHH expression
was not detectable in most cell lines (Fig. S1A).
To represent the two major histological subtypes
of RMS we selected the two alveolar RMS cell lines
RMS13 and RH30, which contain an amplification of
GLI1 [23, 24] and the embryonal RMS cell lines RD and
TE381.T. Importantly, we discovered that the GLI1/2
inhibitor GANT61 and the dual PI3K/mTOR inhibitor
PI103 synergistically induced apoptosis in all RMS cell
lines (Fig. 1A). Calculation of combination index (CI)
illustrates the synergism of this combination treatment
(Suppl. Table S1). Parallel experiments showed that
GANT61 and PI103 cooperated to suppress mRNA levels
of HH target genes GLI1, GLI2 and PTCH (Fig. S2A)
and to reduce phosphorylation of key components of the
PI3K/AKT/mTOR pathway such as AKT, S6 and 4E-BP1
(Fig. S2B). To ensure that this finding is not restricted to
established cell lines, we used primary cultured RMS cells
derived from a tumor sample. Similarly, GANT61 and
PI103 synergized to trigger apoptosis in primary cultured
RMS cells (Fig. 1A), underlining the clinical relevance
of this combination. By comparison, treatment with the
SMO inhibitor GDC-0449 at micromolar concentrations
exerted little effects on cell viability and HH target gene
expression (Fig. S1B) and failed to cooperate with PI103
to induce apoptosis in RMS cells (Fig. S1C).
In addition to pharmacological inhibition of GLI1/2 by
GANT61, we also tested a genetic approach by concomitant
knockdown of GLI1/2 via siRNA. Similarly, GLI1/2
silencing significantly increased PI103-induced apoptosis
(Fig. S3A). In addition to PI103 the dual PI3K/mTOR
inhibitor BEZ235, the PI3K inhibitor GDC-0941 and the
mTOR inhibitors RAD001 and AZD8055 all significantly
increased GANT61-induced apoptosis (Fig.  S4). This
indicates that inhibition of PI3K/AKT/mTOR signaling
at different levels interacts with HH pathway inhibition
to trigger apoptosis in RMS cells. Together, this set of
experiments shows that combined inhibition of GLI1/2 and
PI3K/mTOR synergizes to induce apoptosis in RMS.

GANT61/PI103 cotreatment cooperates to
trigger caspase cleavage and caspase-dependent
apoptosis
To investigate the underlying molecular mechanisms
of the synergistic interaction of GANT61 and PI103 we
analyzed activation of caspases involved in intrinsic
and extrinsic apoptosis signaling. GANT61 and PI103
cooperated to trigger cleavage of caspase-9 into p37 and
p35 fragments, caspase-3 into p17 and p12 active cleavage
fragments and caspase-8 into p43 and p41 fragments
(Fig. 2A). To test whether caspase activity is necessary
for apoptosis we used the broad-range caspase inhibitor

RESULTS
GANT61 and PI103 synergize to induce
apoptosis in RMS cells
To investigate the role of the HH signaling pathway
in RMS we initially evaluated expression levels of
www.impactjournals.com/oncotarget

8723

Oncotarget

Figure 1: GANT61 and PI103 synergize to induce apoptosis in RMS cells. RD, TE381.T, RMS13, RH30 and VJ cells were

treated for 72 hours with indicated concentrations of PI103 and/or GANT61. Apoptosis was determined by DNA fragmentation of
propidium iodide (PI)-stained nuclei using flow cytometry. Mean + S.D. of three independent experiments performed in triplicate are
shown. Corresponding CI values are shown for all cell lines in Suppl. Table 1.

N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone
(zVAD.fmk). Addition of zVAD.fmk significantly reduced
GANT61/PI103-induced apoptosis in all cell lines except
RH30 cells (Fig. 2B). Interestingly, zVAD.fmk treatment
changed the cleavage pattern of caspase-9 and -3 with
accumulation of caspase-9 p35 and caspase-3 p19 cleavage
fragments, whereas caspase-8 cleavage was completely
blocked (Fig. 2A). These findings point to apoptosomemediated cleavage of caspase-9 via induced proximity
www.impactjournals.com/oncotarget

independently of caspase activity and subsequent initial
cleavage of caspase-3 by caspase-9, while autoproteolytic
processing of caspase-3 is blocked by zVAD.fmk. Kinetic
analysis revealed that GANT61/PI103-induced apoptosis
started around 24 hours in TE381.T and VJ cells and
slightly later in RD, RMS13 and RH30 cells (Fig. 2C).
Taken together, these findings indicate that GANT61/
PI103 cotreatment cooperates to induce caspase activation
and caspase-dependent apoptosis.
8724

Oncotarget

Figure 2: GANT61/PI103 cotreatment cooperates to trigger caspase cleavage and caspase-dependent apoptosis. RD,

TE381.T, RMS13, RH30 and VJ cells were treated for indicated times (A, C) or for 48 hours (B) with 1 μM PI103 and/or GANT61 (RD
6 μM; TE381.T 8 μM; RMS13 10 μM; RH30 8 μM; VJ 8 μM) in the presence or absence of 50 μM zVAD.fmk (A, B). In A, caspase
activation was analyzed by Western blotting (asterisks indicate unspecific bands) and active cleavage fragments are indicated by arrow
heads. (B and C) apoptosis was determined by DNA fragmentation of PI-stained nuclei using flow cytometry. Mean + S.D. of three
independent experiments performed in triplicate (B, C) or representative blots (A) are shown; *p < 0.05; **p < 0.01.

GANT61/PI103 cotreatment increases NOXA
and BMF expression

it had little effects on expression of BCL-2, BCL-XL, BAX
and BAK (Fig. S5). This suggests that GANT61/PI103
cotreatment shifts the ratio of pro- and antiapoptotic BCL-2
proteins towards apoptosis.

Since the observed cleavage pattern of caspases
points to engagement of the mitochondrial apoptotic
pathway by GANT61/PI103 cotreatment, we analyzed
the effects of GANT61 and PI103 on expression levels
of pro- and antiapoptotic BCL-2 family proteins, which
play an important role in regulating mitochondrial
apoptosis. Interestingly, treatment with GANT61 alone
or in combination with PI103 led to upregulation of
the proapoptotic protein NOXA (Fig. 3A), which was
accompanied by upregulation of NOXA mRNA by
GANT61/PI103 cotreatment in RD and RH30 cells (Fig. 3B).
In addition, treatment with PI103 alone or in combination
with GANT61 caused a substantial upregulation of BMF
mRNA and protein levels (Fig. 3A,  3B). Furthermore,
GANT61/PI103 cotreatment increased expression of BIM
and reduced MCL-1 protein levels in RH30 cells, whereas
www.impactjournals.com/oncotarget

NOXA and BMF are required for GANT61/
PI103-induced apoptosis
To investigate the functional involvement of NOXA
and BMF in apoptosis induction we knocked down
these proteins by siRNA (Fig. S6). NOXA silencing
significantly reduced GANT61/PI103-induced apoptosis
in all cell lines and BMF knockdown significantly
decreased apoptosis in all but RH30 cells (Fig. 4A).
Simultaneous knockdown of both NOXA and BMF led to
a further significant reduction of GANT61/PI103-induced
apoptosis in RMS13 cells (Suppl. Table S2). These
findings demonstrate that NOXA and BMF contribute to
GANT61/PI103-induced apoptosis.
8725

Oncotarget

Figure 3: GANT61/PI103 cotreatment increases NOXA and BMF expression. RD, TE381.T, RMS13, RH30 and VJ cells were

treated with 1 μM PI103 and/or GANT61 (RD 6 μM; TE381.T 8 μM; RMS13 10 μM; RH30 8 μM; VJ 8 μM) for indicated times (A) or
24 hours (B) A, protein expression of BMF and NOXA was analyzed by Western blotting. B, mRNA levels of pro-apoptotic BCL-2 proteins
were determined by qRT-PCR. Mean + S.D. of three independent experiments performed in triplicate (B) or representative blots (A) are
shown; *p < 0.05; **p < 0.01 comparing treated to untreated cells.

GANT61/PI103-mediated BAX/BAK activation
is required for apoptosis

intact mitochondrial pathway is required for GANT61/
PI103-induced apoptosis.

Next, we investigated the question whether
the observed upregulation of NOXA and BMF
causes activation of BAX and BAK. To this end, we
immunoprecipitated BAK and BAX by conformationspecific antibodies, which specifically bind to their
activated forms. Indeed, treatment with GANT61 and/
or PI103 resulted in activation of BAX and/or BAK
(Fig. 5A). Importantly, genetic knockdown of BAK
by siRNA (Fig. S7) significantly reduced GANT61/
PI103-induced apoptosis (Fig. 5B). These experiments
demonstrate that GANT61/PI103-mediated BAX/BAK
activation is required for apoptosis.

GANT61 and PI103 cooperate to suppress
clonogenic survival, sphere formation and tumor
growth in vivo
Next, we investigated the effects of GANT61/
PI103 co-treatment on clonogenic survival and threedimensional (3D) tumor growth. GANT61 and PI103
cooperated to significantly reduce long-term clonogenic
survival of RMS cells compared to either agent alone
or to control (Fig. 7A, 7B). Also, GANT61/PI103
co-treatment significantly decreased sphere formation in a
3D culture model (Fig. 7C). Finally, we tested the in vivo
antitumor activity of GANT61/PI103 co-treatment using
the chicken CAM model, an established model for tumor
growth [26]. To this end, RMS cells were seeded on the
CAM of chicken embryos and allowed to form tumors
followed by treatment with GANT61 and/or PI103 for
three days. Importantly, GANT61 and PI103 acted in
concert to reduce tumor growth (Fig. 7D, 7E). These
experiments show that GANT61/PI103 co-treatment
suppresses clonogenic survival, sphere formation and
RMS growth in vivo.

Overexpression of BCL-2 or phospho-mutant
MCL-1 rescues GANT61/PI103-induced
apoptosis
To confirm the requirement of the mitochondrial
pathway for GANT61/PI103-induced apoptosis, we
overexpressed BCL-2 or a non-degradable phosphodeficient MCL-1 mutant [25]. Overexpression of
BCL-2 significantly decreased GANT61/PI103-induced
apoptosis, attenuated cleavage of caspase-3, -8 and -9 and
prevented GANT61/PI103-induced activation of BAX
(Fig. 6A–6C). Also, ectopic expression of MCL-1 mutant
significantly decreased GANT61/PI103-induced apoptosis
(Fig. 6D). Vice versa, knockdown of MCL-1 via siRNA
significantly increased GANT61/PI103-induced apoptosis
(Fig. 6E). These findings confirm that signaling via an

www.impactjournals.com/oncotarget

DISCUSSION
Searching for new treatment strategies in RMS, we
focused on the HH signaling pathway, since we previously
reported that aberrant activation of this pathway confers
a poor prognosis in RMS [22]. There is accumulating

8726

Oncotarget

Figure 4: NOXA and BMF are required for GANT61/PI103-induced apoptosis. RD, TE381.T, RMS13, RH30 and VJ cells
were transfected with non-silencing siRNA (siControl) or siRNA targeting BMF and/or NOXA and treated for 48 hours with PI103 (1 μM)
and GANT61 (RD 6 μM; TE381.T 8 μM; RMS13 10 μM; RH30 8 μM; VJ 8 μM). Apoptosis was determined by DNA fragmentation of
PI-stained nuclei using flow cytometry. Mean + S.D. of at least three independent experiments performed in triplicate are shown; *p < 0.05;
**p < 0.01. Statistic analysis comparing combined knockdown to single knockdown is shown in Suppl. Table 2.

www.impactjournals.com/oncotarget

8727

Oncotarget

Figure 5: GANT61/PI103-mediated BAX/BAK activation is required for apoptosis. (A) RD, TE381.T and RH30 cells were
treated with 1 μM PI103 and/or GANT61 (RD 6 μM; TE381.T 8 μM; RH30 8 μM) and activation of BAK and BAX was determined after
24 hours by immunoprecipitation using active conformation-specific antibodies; representative blots are shown. (B) cells were transfected
with non-silencing siRNA (siControl) or siRNA targeting BAK, treated with 1 μM PI103 and GANT61 (RD 6 μM; TE381.T 8 μM; RH30
8 μM) for 48 hours and apoptosis was determined by DNA fragmentation of PI-stained nuclei using flow cytometry. Mean + S.D. of three
independent experiments performed in triplicate are shown; *p < 0.05; **p < 0.01; ns: not significant.
evidence showing that the HH pathway is not only
activated via canonical signaling, but also in a noncanonical manner, which may lead to resistance against
SMO inhibitors [27]. Therefore, we targeted HH signaling
at different levels alone or in combination with inhibition
of HH-interacting pathways.
In this study, we identify a synthetic lethal
interaction of concomitant inhibition of HH and PI3K/
AKT/mTOR pathways in RMS. The combination of the
GLI1/2 inhibitor GANT61 and PI3K/mTOR inhibitor
PI103 is highly synergistic at subtoxic concentrations
of both inhibitors as underscored by calculation of CI
values (CI < 0.2). Similarly, genetic silencing of GLI1
www.impactjournals.com/oncotarget

and GLI2 cooperates with PI103 to induce apoptosis. The
clinical relevance of this combination is emphasized by
experiments using a patient-derived primary tumor sample,
which similarly demonstrates the synergistic interaction
of GANT61/PI103 cotreatment. The potency of this
combination therapy is underlined by our data showing
that GANT61/PI103 cotreatment reduces clonogenic
survival, suppresses 3D rhabdosphere formation and, most
importantly, inhibits tumor growth in an in vivo model of
RMS. Based on these findings, we conclude that combined
GLI1/2 and PI3K/mTOR inhibition is a promising novel
therapeutic approach for synergistic apoptosis induction
and tumor growth reduction in RMS.
8728

Oncotarget

Figure 6: Overexpression of BCL-2 and phospho-mutant MCL-1 rescue GANT61/PI103-induced apoptosis. (A–C),
RD, TE381.T and RH30 cells were transfected with a murine BCL-2 construct or empty vector and treated with 1 μM PI103 and GANT61
(RD 6 μM; TE381.T 8 μM; RH30 8 μM). A, apoptosis was determined after 48 hours by DNA fragmentation of PI-stained nuclei using flow
cytometry. B, caspase activation was determined by Western blotting after 24 hours; arrow heads indicate cleavage fragments; asterisks
indicate unspecific bands; diamond indicates empty lane. C, BAX activation was determined after 24 hours by immunoprecipitation
using active conformation-specific antibodies. (D) RD cells were transfected with a non-degradable phospho-mutant MCL-1 construct
or empty vector, treated with 1 μM PI103 and 6 μM GANT61 and apoptosis was determined after 48 hours by DNA fragmentation of
PI-stained nuclei using flow cytometry (upper panel). Overexpression of the MCL-1 construct was verified by Western blotting (lower panel).
(E) RD cells were transfected with non-silencing siRNA (siControl) or two different siRNAs targeting MCL-1 and apoptosis was determined
after 48 hours by DNA fragmentation of PI-stained nuclei using flow cytometry (upper panel). MCL-1 knockdown was verified by Western
blotting (lower panel). Mean + S.D. of three independent experiments performed in triplicate (A, D, E) or representative blots (B–E) are
shown; *p < 0.05; **p < 0.01; ns: not significant.
www.impactjournals.com/oncotarget

8729

Oncotarget

Figure 7: GANT61 and PI103 cooperate to suppress clonogenic survival, 3D sphere formation and tumor growth
in vivo. (A and B) RD cells were treated for 18 hours with 1 μM PI103 and/or 6 μM GANT61 and clonogenic survival was assessed by

colony formation assay at day 10. Representative images are shown (A); the number of colonies was counted after crystal violet staining
and is expressed as percentage of untreated controls (B) (C) RD cells were treated for 24 hours with 1 μM PI103 and/or 6 μM and spheres
were counted after 15 days. (D and E), RD cells were seeded on the CAM of fertilized chicken eggs, treated with 2 μM PI103 and/or 20 μM
GANT61 for three days and tumor growth was analyzed using H/E-stained paraffin sections of the CAM. Representative pictures of at least
15 tumors (D) and quantification of tumor area (E) are shown. Mean + S.D. of three independent experiments performed at least in triplicate
are shown (B, C, E); *p < 0.05; **p < 0.01. (F) Scheme of the proposed mechanism of GANT61/PI103 induced mitochondrial apoptosis.
GANT61 and PI103 treatment results in NOXA and BMF upregulation and subsequently BAX and BAK activation. BAX/BAK activation
leads to cleavage of caspase-9 and activation of caspase-3 as execution pathway of apoptosis. GANT61/PI103-induced apoptosis is inhibited
by overexpression of BCL-2 or phospho-mutant MCL-1, by knockdown of NOXA, BMF or BAK or by caspase inhibitor zVAD.fmk.
www.impactjournals.com/oncotarget

8730

Oncotarget

further enhances GANT61/PI103-induced apoptosis.
Together, these mechanistic studies underscore that the
mitochondrial pathway plays a critical role in mediating
GANT61/PI103-induced apoptosis.
Canonical as well as non-canonical mechanisms
can cause aberrant HH pathway activation in RMS.
Inherited mutations in PTCH can give rise to RMS in both
humans and mice, and human sporadic RMS samples
were reported to harbor mutations in PTCH or SUFU as
well as amplification of GLI1 and GLI2 loci [24, 35–40].
Furthermore, RMS often exhibit active PI3K/AKT/mTOR
signaling [41] that contributes to non-canonical HH
activation via phosphorylation of GLI1, which potentiates
its transcriptional activity [13]. In line with non-canonical
HH activation in RMS, our study reveals that concomitant
inhibition of GLI and PI3K/mTOR signaling is required
to induce apoptosis in RMS cells. Consistently, GANT61/
PI103 cotreatment leads to profound and sustained
suppression of both HH and PI3K/AKT/mTOR signaling
compared to either treatment alone, highlighting the
crosstalk of these pathways downstream of SMO. By
comparison, we demonstrate that treatment with the SMO
inhibitor GDC-0449 alone or in combination with PI3K/
mTOR inhibition fails to induce apoptosis in RMS cells.
As far as the RMS cell lines used in the present study are
concerned, RH30 and RMS13 cells have been described
to harbor GLI1 amplification [23, 24]. Also, inhibition of
GLI has previously been reported to be more efficient in
RMS cell lines than inhibition of SMO by cyclopamine or
by genetic silencing [42].
While tumors with documented HH activation caused
by LOH of PTCH such as BCC have been described to
respond to SMO inhibitors [43], there is mounting evidence
showing that these inhibitors exhibit limited efficiency
against tumors with non-canonical HH activation, e.g. due
to mutations downstream of SMO, GLI amplification or
activation of HH-interacting pathways such as the PI3K/
AKT/mTOR cascade [13, 16, 44, 45]. In glioblastoma
harboring PI3K/mTOR activation due to PTEN deficiency,
combined inhibition using the SMO inhibitor LDE225
and the PI3K inhibitor BKM120 was necessary to reduce
cell viability and inhibit tumor growth [12]. Likewise,
cotreatment with the SMO inhibitor GDC-0449 and the
mTOR inhibitor RAD001 suppressed tumor growth of
esophageal cancer in vivo [13]. These studies highlight
the need of concomitant inhibition of HH and PI3K/AKT/
mTOR pathways in tumors with non-canonical HH pathway
activation. This approach is currently under evaluation in
clinical trials in pancreatic cancer (i.e. GDC-0449 and
Rapamycin) and in advanced solid tumors (i.e. LDE225
and BKM120) [45].
Co-targeting of HH and PI3K/AKT/mTOR
pathways not only provides a promising strategy to bypass
primary resistance to SMO inhibitors due to non-canonical
HH activation, but also to overcome secondary resistance
to these inhibitors. The development of resistance has

Mechanistic studies revealed that the synergistic
interaction of GANT61/PI103 cotreatment is mediated by
the mitochondrial pathway of apoptosis via upregulation
of the proapoptotic proteins NOXA and BMF, followed
by activation of BAX and BAK and subsequent cleavage
of caspases, as demonstrated by several lines of evidence
(Fig. 7F).
First, single treatment with either inhibitor alone
leads to upregulation of different proapoptotic BH3-only
proteins, which is further increased after combination
treatment. PI103 single treatment upregulates BMF, while
GANT61 single treatment increases NOXA levels. PI3K/
AKT/mTOR inhibition has been shown to repress CAPdependent protein translation resulting in a shift towards
internal ribosome entry site (IRES)-mediated translation
and upregulation of BMF [28]. Also, it is interesting to
note that arsenic trioxide, which can decrease GLI1 and
GLI2 levels [29, 30], has been reported to increase NOXA
mRNA and protein expression [31]. This emphasizes that
HH inhibition can lead to upregulation of NOXA. Our
findings showing that knockdown of NOXA or BMF
attenuates GANT61/PI103-induced apoptosis highlight
the functional relevance and non-redundant functions of
these BH3-only proteins during GANT61/PI103-mediated
apoptosis. The notion that signaling via the mitochondrial
pathway is required for the synergistic induction
of apoptosis is underscored by rescue experiments
showing that inhibition of the mitochondrial pathway by
overexpression of BCL-2, by ectopic expression of a nondegradable MCL-1 mutant or by BAK silencing provides
protection against GANT61/PI103-induced apoptosis.
Second, GANT61 and PI103 cooperate to trigger
caspase activation via the mitochondrial pathway of
apoptosis, as indicated by changes in the cleavage pattern
of caspases upon addition of the broad-range caspase
inhibitor zVAD.fmk. Accordingly, accumulation of the
caspase-9 p35 cleavage fragment upon addition of zVAD.
fmk to GANT61/PI103-treated cells is consistent with
cleavage of the initiator caspase-9 via induced proximity
within the apoptosome, an event that does not require
caspase activity and therefore is not inhibited by zVAD.
fmk [32]. By comparison, reduced generation of the p37
cleavage fragment of caspase-9 upon GANT61/PI103
co-treatment in the presence of zVAD.fmk is in line with
the notion that caspase-3 cleaves caspase-9 into the 37kDa fragment in a feedback amplification loop [33].
Accumulation of the 19-kDa fragment of caspase-3 in
GANT61/PI103-treated cells in the presence of zVAD.fmk
is consistent with increased caspase-9 activity, whereas
subsequent autoproteolytic processing of caspase-3 into
the 12- and 17-kDa fragments is inhibited by zVAD.
fmk [34]. Slight activation of caspase-8 upon GANT61/
PI103 cotreatment is likely caused by one of the effector
caspases such as caspase-3, as it is blocked by zVAD.
fmk. Caspase-8 may initiate a feedback amplification
loop, for example by cleaving BID into tBID, which
www.impactjournals.com/oncotarget

8731

Oncotarget

been documented upon monotherapy with SMO inhibitors
both in humans and mice, e.g. due to acquired mutations
in SMO, GLI2 amplification or PI3K/AKT/mTOR
activation [27, 46, 47]. For example in a mouse model of
medulloblastoma, addition of PI3K inhibitor BKM120 or
PI3K/mTOR inhibitor BEZ235 to the initial treatment with
SMO inhibitor LDE225 markedly delayed the occurrence
of resistance [47].
Our study has important implications for the
development of HH pathway-targeted therapies in RMS.
The identification of synthetic lethality by combined
inhibition of HH signaling at the level of GLI and of
PI3K/mTOR in the present study is relevant for RMS,
since non-canonical mechanisms contribute to aberrant
HH pathway activation. Beyond RMS, our results are also
of broader relevance for other HH-driven cancer with
non-canonical HH activation. One future challenge is the
development of clinically applicable GLI-targeting drugs.
Here, inhibition of bromo and extra C-terminal (BET)
bromodomain proteins may open new perspectives, as
the small-molecule BET bromodomain inhibitor JQ1 has
recently been reported to block GLI transcriptional output
downstream of SMO [48]. Taken together, HH pathwaytargeted therapies may open new perspectives for more
effective treatment options for RMS.

using flow cytometry (FACSCanto II, BD Biosciences,
Heidelberg, Germany) as described previously [52]. Cell
viability was assessed by 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) assay according
to the manufacturer’s instructions (Roche Diagnostics,
Mannheim, Germany).

Determination of colony formation and sphere
formation
For colony assay, cells were treated for 18 hours,
re-seeded as single cells (200 cells/well) in six-well plates
and cultured for additional 10 days before colonies were
stained with crystal violet (Roth, Karlsruhe, Germany)
and counted. For sphere formation, cells were treated for
24 hours and seeded as single cells in stem cell culture
medium in ultra low attachment plates as previously
described [53].

Western blot analysis
Western blot analysis was performed as described
previously [52] using the following antibodies: mouse
anti-caspase-8, mouse anti-NOXA, rat anti-BMF (Alexis
Biochemicals, Grünberg, Germany), mouse anti-AKT,
mouse anti-BCL-2, mouse anti-BAX, rabbit anti-BAK
(BD Bioscience), rabbit anti-caspase-3, mouse anticaspase-9, rabbit anti-pAKT, rabbit anti-p4E-BP1, rabbit
anti-4E-BP1, rabbit anti-pS6, mouse anti-S6, (Cell
Signaling, Beverly, MA), rabbit anti-MCL-1 (Stressgene
Bioreagents, Victoria, BC). Mouse anti-GAPDH (HyTest,
Turku, Finland) or mouse anti-β-Actin (Sigma) were used
as loading controls. Goat anti-mouse IgG, donkey antigoat IgG, goat anti-rabbit IgG conjugated to horseradish
peroxidase (Santa Cruz Biotechnology, Santa Cruz,
CA)) and goat anti-mouse IgG1 or goat anti-mouse
IgG2b (Southern Biotech, Birmingham, AL) conjugated
to horseradish peroxidase were used as secondary
antibodies. Enhanced chemiluminescence was used for
detection (Amersham Bioscience, Freiburg, Germany).
Representative blots of at least two independent
experiments are shown.

METHODS
Cell culture and chemicals
RMS cell lines were obtained from the American Type
Culture Collection (Manassas, VA, USA) and maintained
in RPMI 1640 or DMEM medium (Life Technologies.,
Eggenstein, Germany), supplemented with 10% fetal calf
serum (FCS) (Biochrom, Berlin, Germany), 1 mM glutamine
and 1% penicillin/streptomycin (Invitrogen, Karlsruhe,
Germany). VJ cells were generated from a primary
cultured RMS derived from a patient diagnozed with RMS
(histologically confirmed alveolar rhabdomyosarcoma) and
cultured in DMEM medium. zVAD.fmk was purchased from
Bachem (Heidelberg, Germany). GDC-0449 [49] and GDC0941 were kindly provided by Genetech Inc. (South San
Francisco, CA, USA), PI3K/mTOR inhibitor PI103 [50] was
purchased from Merck Millipore (Darmstadt, Germany) and
GLI1/2 inhibitor GANT61 [51] from Sigma (Deisenhofen,
Germany). BEZ235 and RAD001 were kindly provided
by Novartis Institute for BioMedical Research (Oncology
Basel, Novartis Pharma AG, Basel Switzerland). AZD8055
was obtained from Selleck Chemicals (Houston, Texas).
All chemicals were purchased from Sigma unless indicated
otherwise.

BAX/BAK activation
A total of 1000 μg protein was immunoprecipitated
with mouse anti-BAX antibody (6A7, Sigma) or mouse
anti-BAK (TC-100, Merck Millipore) and 5 μl Dynabeads
Pan Mouse IgG (Dako, Hamburg, Germany). The
precipitate was analyzed by Western blotting using the
BAX NT antibody (Merck Millipore) or BAK antibody
(BD, Bioscience).

Determination of apoptosis and cell viability

Statistical analysis

Apoptosis was determined by analysis of DNA
fragmentation of propidium iodide (PI)-stained nuclei

Statistical significance was assessed by Student’s
t-Test (two-tailed distribution, two-sample, unequal

www.impactjournals.com/oncotarget

8732

Oncotarget

variance). Interaction between PI103 and GANT61 was
analyzed by the Combination index (CI) method based on
that described by [54] using CalcuSyn software (Biosoft,
Cambridge, UK). CI < 0.9 indicates synergism, 0.9–1.1
additivity and > 1.1 antagonism.

Primers are listed in Suppl. Table S3. Melting curves were
plotted to verify the specificity of the amplified products.
The relative expression of the target gene transcript and
reference gene transcript was calculated as ΔΔct. At
least two independent experiments were performed for
each gene.

Transient RNA interference

ACKNOWLEDGMENTS

For transient knockdown by siRNA, cells were
reversely transfected with 10 nM SilencerSelect siRNA
(Invitrogen), control siRNA (4390843) or targeting
siRNAs (s8583 and s8585 for MCL-1; s40385 and s40386
for BMF, s10708 and s10709 for NOXA, s5814 for
GLI1, s5817 for GLI2, s1880 and s1881 for BAK) using
Lipofectamine RNAi Max (Invitrogen) and OptiMEM
(Life Technologies).

We thank T. Klingebiel and S. Wehner for providing
the RMS sample, D. Brücher for expert technical
assistance, and C. Hugenberg for expert secretarial
assistance. This work has been partially supported by
grants from the Deutsche Krebshilfe and BMBF (to S.F.).

Conflict of interest

Transduction

The authors declare no conflict of interest.

For BCL-2 overexpression, cells were transduced
with murine stem cell virus (pMSCV, Clontech,
Mountain View, CA) vector containing mouse BCL-2
or empty vector using the packaging cell line 293T (BD
Biosciences). Stable cell lines were selected with 10 μg/
ml Blasticidin (Invitrogen). For phospho-mutant MCL-1,
cells were transduced with a pCMV vector containing
4A (S64A/S121A/S159A/T163A) and empty vector by
Genentech (South San Francisco) and were selected with
Neomycin (Roth).

REFERENCES
1.	 Gallego Melcon S, Sanchez de Toledo Codina J. Molecular
biology of rhabdomyosarcoma. Clin Transl Oncol. 2007;
9:415–419.
2.	 Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol. 2013;
20:387–397.
3.	 Bridge JA, Liu J, Weibolt V, Baker KS, Perry D, Kruger R,
Qualman S, Barr F, Sorensen P, Triche T, Suijkerbuijk R.
Novel genomic imbalances in embryonal rhabdomyosarcoma
revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma
study. Genes Chromosomes Cancer. 2000; 27:337–344.

CAM assay
CAM assay was done as described previously [26].
Briefly, 106 cells were implanted on fertilized chicken
eggs on day eight of incubation, treated with 2 μM PI103
and 20 μM GANT61 for three days, sampled with the
surrounding CAM, fixed in 4% paraformaldehyde, paraffin
embedded, cut in 5-mm sections and were analyzed by
immunohistochemistry using 1:1 hematoxylin and 0.5%
eosin (H/E). Images were digitally recorded using an
AX70 microscope (Olympus, Center Valley, PA, USA)
and tumor areas were analyzed by ImageJ digital imaging
software (NIH, Bethesda, MA, USA).

4.	 Gorlin RJ. Nevoid basal cell carcinoma syndrome. Dermatol
Clin. 1995; 13:113–125.
5.	 Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR,
Shanley S, Chidambaram A, Vorechovsky I, Holmberg E,
Unden AB, Gillies S, Negus K, Smyth I, Pressman C, et al.
Mutations of the human homolog of Drosophila patched
in the nevoid basal cell carcinoma syndrome. Cell. 1996;
85:841–851.
6.	 Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW,
Bonifas JM, Quinn AG, Myers RM, Cox DR, Epstein EH
Jr., Scott MP. Human homolog of patched, a candidate
gene for the basal cell nevus syndrome. Science. 1996;
272:1668–1671.

Quantitative real-time PCR
Total RNA was extracted using peqGOLD
Total RNA kit from Peqlab Biotechnologie GmbH
(Erlangen, Germany) according to the manufacturer’s
instructions. Total RNA (2 μg) was used to synthesize
the corresponding cDNA using RevertAid H Minus First
Strand cDNA Synthesis Kit (MBI Fermentas GmbH, St.
Leon-Rot, Germany). To quantify gene expression levels,
SYBRGreen based quantitative RT-qPCR was performed
using the 7900HT fast real-time PCR system from
Applied Biosystems (Darmstadt, Germany). Data were
normalized on 28S-rRNA expression as reference gene.
www.impactjournals.com/oncotarget

7.	 Hahn H, Wojnowski L, Zimmer AM, Hall J, Miller G,
Zimmer A. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med.
1998; 4:619–622.
8.	 Ryan KE, Chiang C. Hedgehog secretion and signal transduction in vertebrates. J Biol Chem. 2012;
287:17905–17913.
9.	 Eichberger T, Sander V, Schnidar H, Regl G,
Kasper M, Schmid C, Plamberger S, Kaser A,
8733

Oncotarget

Aberger F, Frischauf AM. Overlapping and distinct transcriptional regulator properties of the GLI1 and GLI2 oncogenes. Genomics. 2006; 87:616–632.

23.	 Roberts WM, Douglass EC, Peiper SC, Houghton PJ, Look
AT. Amplification of the gli gene in childhood sarcomas.
Cancer Res. 1989; 49:5407–5413.

10.	 Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev. 2008; 22:2454–2472.

24.	 Bridge JA, Liu J, Qualman SJ, Suijkerbuijk R, Wenger G,
Zhang J, Wan X, Baker KS, Sorensen P, Barr FG. Genomic
gains and losses are similar in genetic and histologic subsets
of rhabdomyosarcoma, whereas amplification predominates
in embryonal with anaplasia and alveolar subtypes. Genes
Chromosomes Cancer. 2002; 33:310–321.

11.	 Stecca B, Mas C, Clement V, Zbinden M, Correa R,
Piguet V, Beermann F, Ruiz IAA. Melanomas require
HEDGEHOG-GLI signaling regulated by interactions
between GLI1 and the RAS-MEK/AKT pathways. Proc
Natl Acad Sci U S A. 2007; 104:5895–5900.

25.	 Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W,
Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, Belmont
LD, Kaminker JS, O’Rourke KM, et al. Sensitivity to
antitubulin chemotherapeutics is regulated by MCL1 and
FBW7. Nature. 2011; 471:110–114.

12.	 Gruber Filbin M, Dabral SK, Pazyra-Murphy MF,
Ramkissoon S, Kung AL, Pak E, Chung J, Theisen MA,
Sun Y, Franchetti Y, Sun Y, Shulman DS, Redjal N, et al.
Coordinate activation of Shh and PI3K signaling in PTENdeficient glioblastoma: new therapeutic opportunities. Nat
Med. 2013; 19:1518–1523.
13.	 Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li
CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo
L, et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 2012; 21:374–387.

26.	 Hacker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S,
Krauss J, Debatin KM, Fulda S. Histone deacetylase inhibitors cooperate with IFN-gamma to restore
caspase-8 expression and overcome TRAIL resistance
in cancers with silencing of caspase-8. Oncogene. 2009;
28:3097–3110.

14.	 Nolan-Stevaux O, Lau J, Truitt ML, Chu GC, Hebrok M,
Fernandez-Zapico ME, Hanahan D. GLI1 is regulated
through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and
transformation. Genes Dev. 2009; 23:24–36.

27.	 Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP,
Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T,
Bazan JF, Kan Z, Seshagiri S, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in
medulloblastoma. Science. 2009; 326:572–574.

15.	 Seto M, Ohta M, Asaoka Y, Ikenoue T, Tada M,
Miyabayashi K, Mohri D, Tanaka Y, Ijichi H, Tateishi K,
Kanai F, Kawabe T, Omata M. Regulation of the hedgehog
signaling by the mitogen-activated protein kinase cascade in
gastric cancer. Mol Carcinog. 2009; 48:703–712.

28.	 Grespi F, Soratroi C, Krumschnabel G, Sohm B, Ploner
C, Geley S, Hengst L, Hacker G, Villunger A. BH3-only
protein Bmf mediates apoptosis upon inhibition of CAPdependent protein synthesis. Cell Death Differ. 2010;
17:1672–1683.

16.	 Wei L, Xu Z. Cross-signaling among phosphinositide-3
kinase, mitogen-activated protein kinase and sonic hedgehog pathways exists in esophageal cancer. Int J Cancer.
2011; 129:275–284.

29.	 Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall
MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez O,
Macdonald TJ, Albanese C, Toretsky JA, Uren A. Arsenic
trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin
Invest. 2011; 121:148–160.

17.	 Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro
CL, Majumder S. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res. 2012;
72:5048–5059.

30.	 Kim J, Lee JJ, Kim J, Gardner D, Beachy PA. Arsenic
antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A. 2010;
107:13432–13437.

18.	 Fulda S. Tumor resistance to apoptosis. Int J Cancer. 2009;
124:511–515.

31.	 Morales AA, Gutman D, Lee KP, Boise LH. BH3-only
proteins Noxa, Bmf, and Bim are necessary for arsenic
trioxide-induced cell death in myeloma. Blood. 2008;
111:5152–5162.

19.	 Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis
pathways in anticancer chemotherapy. Oncogene. 2006;
25:4798–4811.
20.	 Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol. 2007;
19:488–496.

32.	 Cain K, Bratton SB, Cohen GM. The Apaf-1 apoptosome:
a large caspase-activating complex. Biochimie. 2002;
84:203–214.

21.	 Riedl SJ, Salvesen GS. The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol. 2007; 8:405–413.

33.	 Zou H, Yang R, Hao J, Wang J, Sun C, Fesik SW, Wu JC,
Tomaselli KJ, Armstrong RC. Regulation of the Apaf-1/
caspase-9 apoptosome by caspase-3 and XIAP. J Biol
Chem. 2003; 278:8091–8098.

22.	 Zibat A, Missiaglia E, Rosenberger A, Pritchard-Jones K,
Shipley J, Hahn H, Fulda S. Activation of the hedgehog
pathway confers a poor prognosis in embryonal and fusion
gene-negative alveolar rhabdomyosarcoma. Oncogene.
2010; 29:6323–6330.
www.impactjournals.com/oncotarget

34.	 Han Z, Hendrickson EA, Bremner TA, Wyche JH. A
sequential two-step mechanism for the production of the
8734

Oncotarget

mature p17:p12 form of caspase-3 in vitro. J Biol Chem.
1997; 272:13432–13436.

45.	 Brechbiel J, Miller-Moslin K, Adjei AA. Crosstalk between
hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer Treat Rev. 2014;
40:750–759.

35.	 Tostar U, Malm CJ, Meis-Kindblom JM, Kindblom LG,
Toftgard R, Unden AB. Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU
genes in human rhabdomyoma and rhabdomyosarcoma
development. J Pathol. 2006; 208:17–25.

46.	 Dijkgraaf GJ, Alicke B, Weinmann L, Januario T,
West K, Modrusan Z, Burdick D, Goldsmith R, Robarge K,
Sutherlin D, Scales SJ, Gould SE, Yauch RL, et al. Small
molecule inhibition of GDC-0449 refractory smoothened
mutants and downstream mechanisms of drug resistance.
Cancer Res. 2011; 71:435–444.

36.	 Calzada-Wack J, Schnitzbauer U, Walch A, Wurster KH,
Kappler R, Nathrath M, Hahn H. Analysis of the PTCH
coding region in human rhabdomyosarcoma. Hum Mutat.
2002; 20:233–234.

47.	 Buonamici S, Williams J, Morrissey M, Wang A, Guo R,
Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q,
Ostrom L, Fordjour P, et al. Interfering with resistance
to smoothened antagonists by inhibition of the PI3K
pathway in medulloblastoma. Sci Transl Med. 2010;
2:51ra70.

37.	 Ragazzini P, Gamberi G, Pazzaglia L, Serra M,
Magagnoli G, Ponticelli F, Ferrari C, Ghinelli C,
Alberghini M, Bertoni F, Picci P, Benassi MS.
Amplification of CDK4, MDM2, SAS and GLI genes in
leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma. Histol Histopathol. 2004; 19:401–411.

48.	 Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A,
Bandopadhayay P, Bergthold G, Masoud S, Nguyen B,
Vue N, Balansay B, Yu F, Oh S, et al. Epigenetic targeting of Hedgehog pathway transcriptional output
through BET bromodomain inhibition. Nat Med. 2014;
20:732–740.

38.	 Pressey JG, Anderson JR, Crossman DK, Lynch JC,
Barr FG. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a
report from the Children’s Oncology Group. Pediatr Blood
Cancer. 2011; 57:930–938.

49.	 Robarge KD, Brunton SA, Castanedo GM, Cui Y, Dina
MS, Goldsmith R, Gould SE, Guichert O, Gunzner JL,
Halladay J, Jia W, Khojasteh C, Koehler MF, et al. GDC0449-a potent inhibitor of the hedgehog pathway. Bioorg
Med Chem Lett. 2009; 19:5576–5581.

39.	 Roberts WM, Douglass EC, Peiper SC, Houghton PJ, Look
AT. Amplification of the gli gene in childhood sarcomas.
Cancer Res. 1989; 49:5407–5413.
40.	 Paulson V, Chandler G, Rakheja D, Galindo RL, Wilson K,
Amatruda JF, Cameron S. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer.
2011; 50:397–408.

50.	 Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix
S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bjerke
LM, Kelland L, Valenti M, et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide
3-kinases. Cancer Res. 2007; 67:5840–5850.

41.	 Petricoin EF 3rd, Espina V, Araujo RP, Midura B, Yeung C,
Wan X, Eichler GS, Johann DJ Jr, Qualman S, Tsokos M,
Krishnan K, Helman LJ, Liotta LA. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 2007; 67:3431–3440.

51.	 Lauth M, Bergstrom A, Shimokawa T, Toftgard R.
Inhibition of GLI-mediated transcription and tumor cell
growth by small-molecule antagonists. Proc Natl Acad Sci
U S A. 2007; 104:8455–8460.

42.	 Tostar U, Toftgard R, Zaphiropoulos PG, Shimokawa T.
Reduction of human embryonal rhabdomyosarcoma tumor
growth by inhibition of the hedgehog signaling pathway.
Genes Cancer. 2010; 1:941–951.

52.	 Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM.
The CD95 (APO-1/Fas) system mediates drug-induced
apoptosis in neuroblastoma cells. Cancer Res. 1997;
57:3823–3829.

43.	 Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD,
Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander
PA, Marmur E, Rudin CM, Chang AL, et al. Efficacy and
safety of vismodegib in advanced basal-cell carcinoma.
N Engl J Med. 2012; 366:2171–2179.

53.	 Walter D, Satheesha S, Albrecht P, Bornhauser BC,
D’Alessandro V, Oesch SM, Rehrauer H, Leuschner I,
Koscielniak E, Gengler C, Moch H, Bernasconi M, Niggli FK,
et al. CD133 positive embryonal rhabdomyosarcoma stemlike cell population is enriched in rhabdospheres. PLoS One.
2011; 6:e19506.

44.	 Kool M, Jones DT, Jager N, Northcott PA, Pugh TJ,
Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M,
Milde T, Bourdeaut F, Ryzhova M, et al. Genome sequencing
of SHH medulloblastoma predicts genotype-related response
to smoothened inhibition. Cancer Cell. 2014; 25:393–405.

www.impactjournals.com/oncotarget

54.	 Chou TC. The median-effect principle and the combination
index for quantitation of synergism and antagonism. In:
Chou TC, ed. Synergism and antagonism in chemotherapy.
(San Diego, USA) Academic Press), 1991; pp. 61–102

8735

Oncotarget

